Systematic review of evidence on the clinical effectiveness of Bowen therapy

Technical report prepared by Cochrane Australia

4 November 2024

Contents

[Scope of the technical report 4](#_Toc184287730)

[Appendix A. Study eligibility criteria, identification and selection 5](#_Toc184287731)

[Overview of Appendix A 5](#_Toc184287732)

[Appendix A1. Review questions and criteria for considering studies 5](#_Toc184287733)

[Primary objective was to answer the following question 6](#_Toc184287734)

[Secondary objectives related to the following questions 6](#_Toc184287735)

[A1.1 Criteria for considering studies for this review 6](#_Toc184287736)

[A1.1.1 Types of studies 6](#_Toc184287737)

[A1.1.2 Types of participants 7](#_Toc184287738)

[A1.1.3 Types of interventions 7](#_Toc184287739)

[A1.1.4 Types of outcomes 8](#_Toc184287740)

[Appendix A2. Search methods for identification of studies 10](#_Toc184287741)

[A2.1 Electronic searches 10](#_Toc184287742)

[A2.2 Searching other resources 10](#_Toc184287743)

[A2.3 Public submissions 10](#_Toc184287744)

[Appendix A3. Methods for selecting studies 11](#_Toc184287745)

[A3.1 Selection of studies 11](#_Toc184287746)

[Appendix A4. Results of the search 13](#_Toc184287747)

[Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 10, 2023) 13](#_Toc184287748)

[MEDLINE ALL (Ovid) 1946 to October 3, 2023 13](#_Toc184287749)

[Embase Classic+Embase (Ovid) 1947 to October 3, 2023 14](#_Toc184287750)

[Emcare (Ovid) 1995 to 2023 week 39 14](#_Toc184287751)

[AMED (Ovid) 1985 to September 2023 14](#_Toc184287752)

[CINAHL Complete (EBSCOhost) 14](#_Toc184287753)

[Europe PMC 14](#_Toc184287754)

[ClinicalTrials.gov and WHO ICTRP 14](#_Toc184287755)

[Google Scholar 14](#_Toc184287756)

[Appendix A5. Prioritisation process: methods used to refine the questions addressed in the synthesis 15](#_Toc184287757)

[Prioritisation of populations and grouping of conditions for the summary and synthesis 15](#_Toc184287758)

[Prioritisation and selection of outcomes for the synthesis 15](#_Toc184287759)

[Appendix A6. Final framework for summary and synthesis 16](#_Toc184287760)

[Prioritised outcomes and comparisons 16](#_Toc184287761)

[Appendix A7. Summary of inclusion decisions based on the final framework 17](#_Toc184287762)

[Appendix B. Data collection, analysis and interpretation of findings 18](#_Toc184287763)

[B1 Data extraction and management 18](#_Toc184287764)

[B1.1 Assessment of risk of bias of included studies 19](#_Toc184287765)

[B1.2 Measures of treatment effect 20](#_Toc184287766)

[B1.3 Unit of analysis issues 20](#_Toc184287767)

[B1.4 Dealing with missing data 20](#_Toc184287768)

[B1.5 Assessment of heterogeneity 21](#_Toc184287769)

[B1.6 Assessment of biases due to missing results 21](#_Toc184287770)

[B2 Data synthesis 21](#_Toc184287771)

[B2.1 Meta-analysis 21](#_Toc184287772)

[B2.2 Summary and synthesis when meta-analysis is not possible 22](#_Toc184287773)

[B2.3 Subgroup analysis and investigation of heterogeneity 22](#_Toc184287774)

[B2.4 Sensitivity analyses 22](#_Toc184287775)

[B2.5 Summary of findings tables and assessment of certainty of the body of evidence 22](#_Toc184287776)

[B2.6 Interpretation of findings (evidence statements) 24](#_Toc184287777)

[References for Appendix A and B 26](#_Toc184287778)

[Appendix C. Lists of studies considered for review 28](#_Toc184287779)

[Overview of Appendix C – separate file 28](#_Toc184287780)

[Appendix D. Citations for studies included in the evidence synthesis 29](#_Toc184287781)

[Appendix E. Characteristics of studies included in the review 30](#_Toc184287782)

[Overview of Appendix E – separate file 30](#_Toc184287783)

[Appendix F. Risk of bias assessments 31](#_Toc184287784)

[Appendix G. Differences between the protocol and the review 37](#_Toc184287785)

[Appendix H. Response to comments from the Methodological review 39](#_Toc184287786)

[Appendix I. Abbreviations 40](#_Toc184287787)

#

# Scope of the technical report

This Technical Report includes a complete description of the methods for the review (Appendices A, B and G), results of the search and prioritisation process (Appendix A), citations for studies included in the evidence synthesis (Appendix D), risk of bias assessments for studies contributing to meta-analyses (Appendix F) and abbreviations used in the report (Appendix I).

It also includes an overview of Appendices C and E which are listed below but presented in separate files.

Appendices contained in this file are in light grey rows. Those in separate files are in blue rows.

|  |
| --- |
| Appendix A. Study eligibility criteria, identification and selection |
| Appendix B. Data collection, analysis and interpretation of findings |
| Appendix C. Lists of excluded studies, public submissions, studies awaiting classification, ongoing studies (1 file) |
| Appendix D. Citations for studies included in the evidence synthesis |
| Appendix E. Characteristics of studies included in the evidence synthesis (3 files) |
| Appendix F. Risk of bias assessments for studies contributing to meta-analyses (1 file) |
| Appendix G. Differences between the protocol and the review and methods not used |
| Appendix H. Response to methodological review |
| Appendix I. Abbreviations and list of measures |

# Appendix A. Study eligibility criteria, identification and selection

## Overview of Appendix A

Appendix A is comprised of Appendices A1-A7 (below). These Appendices report the methods (grey rows) and results (blue rows) from the first four stages of the review (Figure A, 1-4). These stages encompass the initial specification of questions to be addressed in the synthesis and criteria for including studies in the review, the specification and implementation of search methods, and the selection of studies. From this set of studies, we compiled information about the populations and outcomes addressed in studies eligible for the review. This information was reviewed by NTWC and NTREAP in order to confirm the grouping of conditions into population groups and prioritise outcomes for inclusion in the evidence synthesis.

|  |
| --- |
| Appendix A1. Review questions and criteria for considering studies for this review |
| Appendix A2. Search methods for identification of studies |
| Appendix A3. Methods for selecting studies  |
| Appendix A4. Results of the search |
| Appendix A5. Prioritisation process: methods used to refine the questions addressed in the synthesis |
| Appendix A6. Final framework: synthesis questions and criteria for including studies in each synthesis |
| Appendix A7. Summary of inclusion decisions based on the final framework |

Appendices A1-A3 and A5 report the pre-specified methods from the protocol endorsed by NTWC, prospectively registered on the International prospective register of systematic reviews (PROSPERO ID [CRD42023467144](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=467144)). Appendix A6 reports the framework that resulted from the prioritisation process shown in Figure A and described in Appendix A5. The framework was finalised prior to commencing data extraction (Figure A, panel 5). It defines the scope of the evidence synthesis and specifies the synthesis questions and associated PICO (population, intervention, comparator, outcome) criteria for including studies in each synthesis.



**Fig A** | Staged approach for developing the questions and analytic framework for this review. Due to the small number of studies eligible for the review all studies with active comparators were included in the evidence synthesis.

# Appendix A1. Review questions and criteria for considering studies

The overall objective of this systematic review is to examine the evidence for the clinical effectiveness of Bowen therapy in preventing and/or treating injury, disease, medical conditions or preclinical conditions [1]. The questions for the review follow (framed as primary and secondary objectives). An initial analytic framework for the review was presented in the protocol to illustrate the breadth of questions and a possible structure for the synthesis, with indicative populations and outcome domains (Figure A1.1). The framework was refined through the prioritisation process (described in Appendix A5) leading to the final framework and criteria for including studies in the synthesis (Appendix A6). Outcomes listed in the objectives were agreed through the prioritisation process.

## Primary objective was to answer the following question

1. What is the effect of Bowen therapy compared to an inactive control (no intervention, sham, placebo, wait list control, or a co-intervention offered to both groups, or continuation of usual care) on outcomes for each underlying condition, pre-condition, injury or risk factor? (see Appendix G)

## Secondary objectives related to the following questions

1. What is the effect of *Bowen therapy* compared to evidence-based treatments (active comparators) on outcomes for each underlying condition, pre-condition, injury or risk factor?
2. What evidence exists examining the effects of *Bowen therapy* compared to other active comparators?

Given the very small number of studies in the review, we report on the effects of Bowen therapy compared to any active comparator (i.e. not limited to “gold standard”) (see Appendix G).



**Fig A1.1 |** Initial analytic framework for the review showing example population groups and outcome domains for the Evidence Synthesis. The framework was informed by research on the outcomes (and underlying conditions) for which Bowen therapy is commonly sought or prescribed in Australia, the wider literature on Bowen therapy, and consideration of frameworks for classifying disease and outcomes [2, 3].

## A1.1 Criteria for considering studies for this review

### A1.1.1 Types of studies

We included randomised controlled trials (RCTs) (including individually and cluster randomised, and cross-over trials).

Controlled trials in which the allocation sequence did not include a truly random element, was predictable, or was not adequately concealed from investigators were eligible as long as there was an attempt to have some kind of ‘randomisation’ to groups. Examples included studies that used methods for sequence generation based on alternation, dates (of birth or attendance at a clinic) and patient record numbers [4].

Non-randomised studies of interventions (NRSIs) with specific design features that are suitable for estimating a causal effect were eligible for inclusion in the review, in line with current Cochrane guidance. While study design labels were used as an aid to communicating about eligible designs and for use in the review, eligibility decisions were based on assessment of the specific design features of each study rather than the label used by the study authors (see checklist Appendix 2 in protocol [published on PROSPERO](https://www.crd.york.ac.uk/PROSPEROFILES/467144_PROTOCOL_20230926.pdf) CRD) [5, 6].

Eligible non-randomised study designs were those in which the following features are present.

* The intervention may be allocated to individuals or clusters. We anticipated that Bowen therapy (or the control) would be allocated to individuals in most studies, although clustering was likely in these studies given the way in which Bowen therapy lessons are delivered (i.e. the same teacher may deliver the intervention to multiple participants) [7].
* Treatment groups may be formed by some action of the researchers or in the course of usual treatment decisions (including healthcare decision makers, practitioners or participants/patients/peoples’ choices).
* Studies must include a contemporaneous control.
* There must be an attempt to control for confounding (either by using methods that control in principle for confounding or that control for observed covariates)
* The design must be suitable for estimating a causal effect.

We excluded:

* Studies for which available reports had not been peer reviewed (grey literature, including theses).

#### Date and language restrictions.

There were no restrictions on publication date.

Potentially eligible studies published in languages other than English were not eligible for synthesis. In accordance with the protocol, these studies were to be included in the list of studies ‘Awaiting classification’ and coded according to whether they were likely to be eligible or whether eligibility could not be determined.

### A1.1.2 Types of participants

Studies involving participants with any disease, medical condition, injury, or preclinical condition were eligible for the review. This included healthy participants with clearly-identified risk factors (evident from study eligibility criteria or baseline data). There were no restrictions on age.

We expected that studies would include participants that fall within broad population groups as indicated in the initial framework Figure A1.1. The population groups encompass conditions identified in Bowen therapy literature and the PRACI survey as often treated by Bowen practitioners [8]. Decisions about which populations to include in the evidence synthesis and how these populations would be grouped for synthesis were made through the prioritisation process (see Appendix A5) and reported in the final framework (see Appendix A6).

***Excluded populations***. Healthy populations seeking health improvement.

Studies that included both healthy participants and participants eligible for the review were to be included if separate data were available or a majority of participants met the review eligibility criteria [9]. No such studies were included.

### A1.1.3 Types of interventions

For the purpose of this review, Bowen therapy is defined as “a remedial hands-on technique based on the use of gentle pressure and release of the soft connective tissue (fascia) of the body” [excerpt from [10]].

Because of the potential challenge of distinguishing Bowen therapy from related modalities, such as connective tissue manipulation (CTM), and the likelihood of identifying studies in which the defining techniques and principles of the Bowen therapy were incompletely reported, studies were included if the therapy was described as Bowen therapy (or other synonyms). Studies that failed to mention or describe the intervention as Bowen therapy (or other synonyms) were excluded.

Bowen therapy treatments were eligible irrespective of the training or qualifications of the practitioner, the setting in which Bowen therapy was used, and the dose and duration of treatment. More details about each of these intervention features is provided under data extraction (see B1).

#### Comparisons

1. Bowen therapy *versus* any inactive comparator (no intervention, sham, placebo, wait list control, or a co-intervention offered to both groups, or continuation of usual care).
2. Bowen therapy *versus* any active comparator (separated by type of comparator) (see Appendix G).

Any co-intervention was eligible (i.e. pharmacological or non-pharmacological). Usual care comparators were eligible if there was an explicit statement that indicated that participants could continue to access their routine care or therapy (including self-care). Where a comparator labelled as ‘usual care’ involved a defined intervention (i.e. specific treatments and processes selected by the researchers), this was deemed to be either an active intervention (if restricted to the comparator group) or a co-intervention (if able to be accessed by both groups, e.g. continuation of a specific medication).

***Excluded comparisons***. In line with the main review objective, which is to examine the effects of Bowen therapy rather than the comparative effects of different Bowen therapy treatments, we excluded head-to-head comparisons of Bowen therapy. For example, comparisons of Bowen therapy administered by people with different qualifications or specialisations (e.g. Bowen practitioner vs. other health professional), or comparisons of different treatment schedules.

### A1.1.4 Types of outcomes

We considered for inclusion in the review any outcome that aligned with the reasons why Bowen therapy is sought by patients and prescribed by practitioners. In principle, this could include any patient-important outcome that helps elucidate the effects of Bowen therapy on an underlying condition or its symptoms, recovery, rehabilitation, or prevention of disease among people with specific risk factors or pre-conditions. Example outcome domains were shown in the initial analytic framework to illustrate the breadth of outcomes likely to be relevant across a wide range of conditions (Figure A1.1). The outcome domains were based on ICD11 codes and the COMET outcome taxonomy [2, 3]. These systems provide a widely agreed and understood structure for categorising different outcomes.

Studies were included in the review irrespective of the outcome(s) measured, but the summary and synthesis was limited to outcomes considered to be critical or important for each population group. Outcomes for inclusion in the synthesis were determined through the prioritisation process described in Appendix A5.

The outcome domains determined to be critical or important for the synthesis were as follows (see Appendix A6 and Figure A6.1 for details).

* pain
* sleep quality
* fatigue
* emotional functioning and mental health
* health-related quality of life
* physical function (disability & mobility)
* global symptoms

From each study, we selected only one outcome per outcome domain for data extraction (results), risk of bias assessment and inclusion in the synthesis. In selecting outcomes for synthesis, we considered the outcome measure, timing of outcome measurement and data reported as follows.

***Outcome measures.***For each of these outcome domains, we considered for inclusion any measure of the outcome. Where studies reported multiple outcomes within an outcome domain, we used a population-specific hierarchy of outcomes measures to select the most relevant and valid outcome. The hierarchy of measures was proposed by the review team and agreed through the prioritisation process.

***Outcome timing.*** Where trials reported outcomes measured at multiple timepoints, we selected the first measurement taken after the end of the Bowen therapy intervention period (i.e. if Bowen therapy was administered three times over a week, we took the first measure after the third administration).

***Data reported***

* When authors reported results for both change scores (change from baseline) and post-intervention (final) values, we selected results for final values.
* If data for the preferred measure was incompletely reported or uninterpretable, we selected another measure.

***Excluded outcomes.*** experience of care (e.g. satisfaction), safety, quality, and economic outcomes.

# Appendix A2. Search methods for identification of studies

### A2.1 Electronic searches

Studies were sought from the following databases: Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 10, 2023), MEDLINE (Ovid), Embase (Ovid), Emcare (Ovid), AMED (Ovid), CINAHL (EBSCOhost) and Europe PMC. In addition, we searched two clinical trial registers for reports of ongoing or unpublished studies (ClinicalTrials.gov and WHO International Clinical Trials Registry Platform).

The search strategy comprised the text words bowen, bowtech or bowenwork and, where available, the relevant subject heading term. No study design filter was applied. Searches were run on 5 October 2023 and were not limited by language, year of publication or publication status (see Appendix A4).

### A2.2 Searching other resources

We searched the first 10 pages of Google Scholar using the following terms and phrases in the title: "bowen therapy", "bowen technique", "bowen treatment", "bowen practice", bowenwork and bowtech.

We reviewed the studies included in the 2015 evidence evaluation for Bowen therapy and examined the reference lists of included studies and any other relevant systematic reviews. We conducted forward citation searches for studies included in the review using [citationchaser](https://estech.shinyapps.io/citationchaser/).

Finally, we searched PubMed for retracted publications, expressions of concern and published errata, as well as the Retraction Watch database.

### A2.3 Public submissions

Citations provided by the public (via the Department’s call for evidence ) were deduplicated against the records retrieved by the search and screened for eligibility. We examined the reference lists of any relevant systematic reviews.

# Appendix A3. Methods for selecting studies

### A3.1 Selection of studies

Records from CENTRAL, PubMed, AMED and Emcare were imported into EndNote and duplicates removed. All remaining records were imported into Covidence for screening. Records submitted through the Department’s call for evidence were first deduplicated against these records, with the remaining unique records screened to confirm their eligibility (inclusion decisions were recorded for duplicate and non-duplicate records).

Two reviewers (MM, SM) piloted guidance for title and abstract screening on a sample of 50 records to ensure the eligibility criteria were applied consistently. All records were reviewed independently by two reviewers at both the title and abstract screening and full-text review stages in Covidence. Disagreements at either stage were resolved by consensus among members of the review team. Advice from NTWC regarding inclusion was not required.

While screening full-text study reports in Covidence, we extracted the trial register and registry record number (if reported) into notes in Covidence. On completion of study report screening, we matched any registry record details in the included study notes (e.g. registry record number) with the registry records search results.

Unmatched registry records were then screened to identify potentially eligible trials for which there was no published report to include in a list of ‘ongoing studies’ (Appendix C4) and for assessment of bias due to missing results (B1.6).

Published protocols for studies confirmed as meeting the eligibility criteria, but for which results were not available in a published report, were checked against potentially eligible trials identified from registry records and included in the list of ‘ongoing studies’ (Appendix C4). These were also considered in the assessment of bias due to missing results (B1.6)

The following categories of studies were to be included in a list of ‘studies awaiting classification’, if identified:

* Studies that were only published as abstracts or for which a full report was not available (i.e. we did not seek further information from study authors to confirm eligibility).
* Studies for which a full report was available but the report was incomplete or ambiguous such that eligibility based on one or more PICO criteria or study design could not be confirmed.
* Studies confirmed as likely to be eligible, but for which no English language translation of the full-text publication was available.
* Studies for which eligibility could not be confirmed following translation of the title and abstract using Google translate (Figure A3.1.1)
* Studies for which there were concerns about data that could not be resolved from full report(s) (e.g. where there were important discrepancies in study characteristics or data reported across multiple publications from the same study).

Translate title + abstract

Is the study likely to be eligible?

Study unlikely to be eligible

Exclude

Unclear. translation provides insufficient information

List in 'Characteristics of studies awaiting classification'

Study likely (or very likely) to be eligible

List in 'Characteristics of studies awaiting classification'

**Fig. A3.1.1 |** Flowchart showing handling of studies in languages other than English (reproduced from NHMRC framework for natural therapies systematic reviews [11]).

Studies that did not meet the eligibility criteria were excluded and the reason for exclusion was recorded at full-text screening. These studies are included in a list of excluded studies in which the reason for exclusion is reported (Appendix C1).

The search and study selection steps are summarised in the PRISMA flow diagram in Appendix A7.

For studies that originated from the call for evidence we recorded and reported exclusion decisions irrespective of whether the study was excluded during title and abstract screening or full text review. We documented the flow of these studies through the review in the PRISMA flow chart and in Appendix C2.

#### Dealing with duplicate and companion publications

Multiple publications to the same study (e.g. protocols, trial registry entries, trial reports) were identified and linked at the study selection stage in Covidence. Identification and linking of multiple reports were also checked at data extraction in REDCap [12, 13]. Each study was given a unique identifier and all linked records are cited in the final report. Records were matched using trial registry numbers.

#### Dealing with multiple study IDs

If multiple study reports resulted in the same study ID (Author Surname, Year) and were reporting the same study, the study ID for index report was given the suffix ‘.1’ after the Year (e.g. Ziyaeifard 2017.1), and the study ID for the secondary report was given the suffix ‘.2.’ (e.g. Ziyaeifard 2017.2).

If multiple study reports resulted in the same study ID (Author Surname, Year) and were reporting different studies, the study IDs for each study were given the suffix ‘a’, ‘b’, etc after the Year (e.g. Ebrahimi 2021a, Ebrahimi 2021b) to differentiate them.

# Appendix A4. Results of the search

**Bibliographic databases**

The search of bibliographic databases retrieved 300 records. After removing duplicates in EndNote and Covidence, 158 records were screened at title/abstract. The search strategies for each database are given below. The PRISMA flow diagram in Appendix A7 summarises inclusion decisions following title/abstract screening.

**Trial register records**

The search of ClinicalTrials.gov and WHO ICTRP retrieved 55 records, of which 8 were duplicates. Of the 47 unique records screened, 27 were ineligible and 20 eligible. Three of the eligible records are linked to the studies included in the review and 17 are unpublished (see Appendix C4). All but one of the 17 ongoing studies were registered within the last 4 years. As such, 16 studies were judged likely to be ongoing and one unlikely to be published (registered in 2009).

**2015 evidence evaluation for Bowen therapy**

The 2015 overview of Bowen therapy identified one systematic review that identified studies of Bowen therapy [14] (the other review did not include any studies of Bowen therapy). The review included one randomised trial and two quasi-experimental studies. All three studies were retrieved by our search but did not meet the eligibility criteria (the randomised trial included only healthy participants and the non-randomised studies were both case series).

**Forward citation searching**

We used [citationchaser](https://estech.shinyapps.io/citationchaser/) for 5 of the included studies for which we had DOIs or PubMed IDs. These 5 studies were cited 13 times and contributed 12 unique records for screening in Covidence, one of which was included in the review (Qamar 2023).

**Google Scholar**

Scanning the references of the first 10 pages yielded three studies for which the full text was reviewed.

**Public submissions**

Twenty-nine (29) citations were received from the public and key stakeholders (via the Department), NTREAP and NTWC. Of these, 6 were duplicates, 13 were retrieved by our search, 5 were added to Covidence for screening and 5 were excluded (one duplicate registry entry; one master’s thesis; two unpublished conference abstracts; one systematic review). Eligibility decisions for the 23 unique records are reported in Appendix C2. One of the submission references (Dalal 2020) was included in the review.

**Retractions and published errata**

No records were retrieved from PubMed or the Retraction Watch database.

**Search strategies**

### Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 10, 2023)

|  |  |  |
| --- | --- | --- |
| **#** | **Search strategy** | **Records** |
| 1 | ((bowen NEAR/1 (therap\* or technique\* or treat\* or practice\* or practitioner\* or fascia\*)) or bowtech or bowenwork):ti,ab,kw | 35 |

### MEDLINE ALL (Ovid) 1946 to October 3, 2023

|  |  |  |
| --- | --- | --- |
| **#** | **Search strategy** | **Records** |
| 1 | ((bowen adj1 (therap\* or technique\* or treat\* or practice\* or practitioner\* or fascia\*)) or bowtech or bowenwork).af. [af=all fields] | 32 |

### Embase Classic+Embase (Ovid) 1947 to October 3, 2023

|  |  |  |
| --- | --- | --- |
| **#** | **Search strategy** | **Records** |
| 1 | Bowen Therapy/ | 9 |
| 2 | ((bowen adj1 (therap\* or technique\* or treat\* or practice\* or practitioner\* or fascia\*)) or bowtech or bowenwork).ti,ab,kf. | 37 |
| 3 | or/1-2 | 42 |

### Emcare (Ovid) 1995 to 2023 week 39

|  |  |  |
| --- | --- | --- |
| **#** | **Search strategy** | **Records** |
| 1 | Bowen Therapy/ | 2 |
| 2 | ((bowen adj1 (therap\* or technique\* or treat\* or practice\* or practitioner\* or fascia\*)) or bowtech or bowenwork).af. | 28 |
| 3 | or/1-2 | 28 |

### AMED (Ovid) 1985 to September 2023

|  |  |  |
| --- | --- | --- |
| **#** | **Search strategy** | **Records** |
| 1 | bowen\*.mp. [mp=abstract, heading words, title] | 27 |

### CINAHL Complete (EBSCOhost)

|  |  |  |
| --- | --- | --- |
| **#** | **Search strategy** | **Records** |
| 1 | ( TI (bowen W1 (therap\* or technique\* or treat\* or practice\* or practitioner\* or fascia\*)) or bowtech or bowenwork ) OR ( AB (bowen W1 (therap\* or technique\* or treat\* or practice\* or practitioner\* or fascia\*)) or bowtech or bowenwork ) OR MW (bowen W1 (therap\* or technique\* or treat\* or practice\* or practitioner\* or fascia\*)) or bowtech or bowenwork )  | 116 |

### Europe PMC

|  |  |  |
| --- | --- | --- |
| **#** | **Search strategy** | **Records** |
| 1 | (TITLE:"bowen technique") OR (ABSTRACT:"bowen technique") OR (TITLE:"bowen therapy") OR (ABSTRACT:"bowen therapy") OR (TITLE:"bowenwork") OR (ABSTRACT:"bowenwork") OR (TITLE:"bowtech") OR (ABSTRACT:"bowtech") | 20 |

### ClinicalTrials.gov and WHO ICTRP

Bowen (limited to Intervention/treatment in ClinicalTrials.gov) (n=29) and Bowen (limited to Intervention in WHO ICTRP) (n=26)

### Google Scholar

(allintitle: "bowen therapy" OR "bowen technique" OR "bowen treatment" OR "bowen practice" OR bowenwork OR bowtech)

# Appendix A5. Prioritisation process: methods used to refine the questions addressed in the synthesis

The final synthesis questions, and criteria for including studies in each synthesis, were decided through the pre-specified prioritisation process (Figure A). The process was designed to minimise bias in the selection of results for inclusion in the synthesis and ensure coverage of populations and outcomes relevant to the Australian context. All information provided to NTREAP, NTWC and the NHMRC was de-identified and presented in aggregate form so that it was not possible to identify the studies (no bibliographic information, titles etc). No information was provided about the number of studies, number of participants, methodological quality of studies or results.

### Prioritisation of populations and grouping of conditions for the summary and synthesis

There was no need to limit populations in this review, so the provision in the protocol to prioritise populations (conditions) for inclusion in the synthesis was not implemented. NTWC endorsed the proposal to structure the synthesis by the population groups outlined in the analytic framework.

### Prioritisation and selection of outcomes for the synthesis

For each population, we collated information about the outcomes addressed in all eligible studies. The purpose was twofold: (1) to enable prioritisation of the most important **outcome domains** for each population (irrespective of whether studies measured these domains), and (2) to facilitate selection of the **most relevant results** from each study.

***Prioritisation of outcome domains***

* All outcomes and outcome measures were listed under an **outcome domain** from the initial analytic framework for the review (Figure A1.1). For outcomes not covered by the initial framework, additional outcome domains were specified allowing categorisation of all outcomes and measures.
* For each condition, NTWC, with input from NTREAP, rated **outcome domains** as critical, important or of limited importance for understanding the effects of Bowen therapy on each population group. The intent was to identify up to 7 outcome domains for which results would be reported.
* Only critical and important outcome domains were considered in the summary and synthesis.

***Outcome selection.*** From each study, we selected one result per outcome domain for data extraction, risk of bias assessment and reporting of results in the summary and synthesis (using the standardised mean difference to combined effects measured on different scales see B1.2 and B2.1). Selecting one result per study for inclusion in each analysis ensures that individual studies do not receive too much weight. In addition, we aimed to ensure that all studies that should contribute to each synthesis were included.

Overall, the approach deals with multiplicity of results that arises when

1. the outcomes and measures of outcome domain vary across studies;
2. individual studies report results for multiple outcomes, measures and timepoints within an outcome domain (e.g. for HR-QoL, reporting an overall score and subscale scores for specific domains of HR-QoL).

To determine which results to select the following was done.

* For each outcome domain, we presented an initial ranking of all outcomes and measures. Where available, the ranking was informed by recommendations in core outcome sets, outcome hierarchies in published Cochrane reviews, and systematic reviews of outcome measures (i.e. to establish relevance, validity, and reliability).
* The NTWC considered the ranking and either confirmed or reranked the outcomes and measures.
* The highest ranked outcome/measure was selected from each study for each outcome domain.
* If data for the highest ranked outcome/measure could not be included in the analysis (e.g. due to incomplete reporting of data), this was reported and the next highest ranked outcome was selected (and so forth).
* Where an outcome measure was potentially eligible for more than one outcome domain, we selected the measure that enabled us to include a study in the largest number of syntheses (e.g. if a study reported scores for the psychological and physical domains of a HR-QoL measure, but no measure of emotional functioning and mental health (EFMH), we chose the physical domain for HR-QoL and the psychological domain for EFMH).

# Appendix A6. Final framework for summary and synthesis

Figure A6.1, panel A shows the final analytic framework for the evidence summary and synthesis. The framework provides a guide to the structure of the synthesis and reporting of results (see caption for details). We included all eligible studies in the summary and synthesis (i.e. no limitations by population or condition).

### Prioritised outcomes and comparisons

The outcome domains specified in the initial analytic framework were endorsed. Sleep quality, fatigue, and global symptoms were not included in the list of domains rated by NTWC, but are retained in the framework because of their relevance to populations/conditions for which no studies were found. Where trials measured outcomes at multiple timepoints, we selected the first measurement after the end of the intervention period (i.e. if Bowen therapy was given three times over a week, we took the first measure after the third administration).

Because there were few studies, we broadened criteria for inclusion of outcomes and comparisons as follows.

* We included HR-QoL and physical function outcomes irrespective of population (i.e. not limited to chronic or longer-term conditions), duration of Bowen therapy (i.e. not limited to weeks or longer) and length of follow-up (not limited to time-frames likely to detect meaningful improvement).
* Any active comparator was included (reported as separate comparisons).



**Fig A6.1** | Final analytic framework for the review as agreed through the prioritisation process (Appendix A5).
Panel A, columns 1 to 3 show the populations, comparisons and outcome domains eligible for the evidence synthesis. Column 4 shows the populations, comparisons and outcome domains for which studies were available. Results are reported for each population group in the section indicated in column 1. Study-level data and meta-analyses are presented for the primary comparison in the forest plot indicated in column 4. Panel B shows outcome domains rated as of limited importance. Population groups are those reported by Bowen therapists as often treated [15] except those marked \*

# Appendix A7. Summary of inclusion decisions based on the final framework

The flow of studies through the review is summarised in Figure A7.1, the PRISMA flowchart. Inclusions for each synthesis are reported in Figure A6.1 and described in the main report.

**Fig. A7.1** | PRISMA diagram showing the flow of studies through the review (reproduced from main report Fig. 4.1.1). \*see main report section 4.1 for flow of ongoing studies and public submissions \*\*Studies are the unit of interest in the review. Each study could have multiple reports. CoIS: characteristics of included studies.

# Appendix B. Data collection, analysis and interpretation of findings

## B1 Data extraction and management

Study data were collected and managed using REDCap electronic data capture tools hosted at Monash University [12, 13]. The form for extracting results data was developed by the review biostatistician (JM). The form was developed for use by our team for the natural therapies reviews and had been applied to over 200 trials in the first review we conducted. Two authors (MM and SB) pre-tested the data extraction and coding form on a pilot study. Both authors discussed the coding after one author (MM) had reviewed the extracted and coded data on study characteristics for completeness, accuracy and consistency. Revisions to the data extraction form were made as required to maximise the quality and consistency of data collection.

We implemented a two-step process for data extraction. In the first step, studies were triaged by a senior author (MM). For each study we coded population groups, outcome domains and comparisons, and allocated the study to analyses according to the analytic framework for the review. We listed all outcomes measured and selected the outcomes for inclusion in the synthesis according to our pre-specified decision rules. During triage, study eligibility was confirmed and basic checks of methodology were done (e.g. confirming that a trial met the minimum requirements for randomisation). Questions about coding, allocation to analyses and outcome selection were referred to a senior author (SB).

For each included study, one review author (MM) then extracted study characteristics and quantitative data using the data extraction and coding form. A second author (SB) independently verified the coding, allocation to analyses, outcome selection and data extraction. All queries related to the quantitative data were referred to a biostatistician (ST). Discrepancies were resolved through discussion with a senior author (SB, JM) if agreement could not be reached or for more complex scenarios.

Where available, we extracted information relating to the characteristics of included studies and results as follows.

1. Study identifiers and characteristics of the study design
* Study references (multiple publications arising from the same study were matched to an index reference; code as index paper, protocol, registry entry, results paper 1, 2, …)
* Study name, location (country), enrolment dates (not reported by most studies), and trial registration number
* Study design (categorised as ‘individually randomised’, ‘cluster randomised’, ‘crossover’, or ‘NRSI’); whether clustering was likely to arise because of the way Bowen therapy was delivered (e.g. at a regular clinic such as for chemotherapy; this information was used to determine which risk of bias tool to use for assessment).
* Funding sources and funder involvement in study, financial and non-financial interests declared by investigators, potential conflicts (reviewer judgment), ethics approval.
1. Characteristics of each intervention group (including comparator groups)
* Characteristics of the intervention covering domains of the Template for Intervention Description and Replication (TIDieR) checklist [16]
* Bowen therapy intervention goal (coded, for example: relieve symptoms of a condition, prevent a condition among people with risk factors)
* Coding of comparators (e.g. inactive – sham, inactive – no intervention, active - massage)
* Number of participants: randomised to each group, at follow up for selected outcome, and included in analysis and reasons for loss to follow-up
1. Characteristics of participants
* Participant eligibility criteria (verbatim; precis of key criteria to characterise population)
* Participant characteristics: age (e.g. mean, median, range), sex
* Population group: coded using categories specified in the final analytic framework for the review (e.g. chronic musculoskeletal pain, headache or migraine, other chronic conditions)
* Condition: specific underlying condition as described in study (e.g. cervical spine pain; chronic primary pain), including information about severity (if relevant) and closest ICD-11 code.
* Treatment/procedure: applied to studies in which Bowen therapy was administered for the relief of symptoms or side effects of a treatment or procedure for an underlying condition (e.g. chemotherapy). Could include pharmacological treatment (e.g. chemotherapy), surgical, diagnostic or other procedures (as described in study).
* Other characteristics of importance within the context of each study
1. Outcomes assessed and results
* Outcomes measured (list of all outcomes categorised as ‘eligible’ or ‘ineligible’ and categorised according to the final analytic framework; measures used for each)
* For outcomes selected for inclusion in the summary and synthesis of results:
	+ Outcome domain: categorised according to the outcome domains specified in the final analytic framework for the review (e.g. pain, emotional functioning and mental health, health-related quality of life, physical function)
	+ Outcome as described in the included study (verbatim or precis)
	+ Measurement method (e.g. WOMAC; overall score and pain, function and stiffness subscales), information required to interpret the measure (scale range and direction, minimally important difference) and timing of outcome measurement (exact timing; described in relation to timing of Bowen therapy (e.g. immediately after end of Bowen therapy intervention period)
	+ Results including: summary statistics by group (means and standard deviations, or number of events for outcomes that have been dichotomised, and sample size), estimates of intervention effect (e.g. mean differences (or adjusted mean differences), confidence intervals, t-values, p-values, or risk ratios/odds ratios for binary outcomes).
	+ Data required to support risk of bias judgements (see Assessment of risk of bias of included studies) [17]

### B1.1 Assessment of risk of bias of included studies

#### B1.1.1 Assessment of risk of bias in RCTs

We assessed the risk of bias in included studies using the revised Cochrane ‘Risk of Bias’ tool (RoB 2) for randomised trials [4, 17] for each outcome included in the synthesis.

RoB 2 addresses five domains:

* bias arising from the randomisation process;
* bias due to deviations from intended interventions;
* bias due to missing outcome data;
* bias in measurement of the outcome;
* bias in selection of the reported result.

We applied review-specific guidance developed for the suite of natural therapies reviews to ensure consistency across reviewers. This guidance had been used by the author team to assess over 200 natural therapies studies prior to application in the current review. One review author (MM) then applied the tool to the selected results from each study following the RoB 2 guidance [4], and a second author (SB) checked assessments. Areas of uncertainty and frequently asked questions were shared with extractors to promote concordance. Advice was sought from the lead reviewer (SB) where there was uncertainty. Supporting information and justifications for judgements for each domain (low, some concerns, high risk of bias) was recorded. We derived an overall summary of the risk of bias from each assessment, following the algorithm in the RoB 2 guidance as implemented in the Excel assessment tool [4].

When multiple effects of the intervention using different approaches were presented in the trial report, we selected one effect for inclusion in the meta-analysis and for risk of bias assessment. The selected effect was chosen according to the following hierarchy, which orders the approaches from (likely) least to most biased for estimating the *effect of assignment to the intervention*: 1. the effect that corresponds to a full intention-to-treat analysis, where missing data have been multiply imputed, or a model-based approach has been used (e.g. likelihood-based analysis, inverse-probability weighting); 2. the effect corresponding to an analysis that adheres to intention-to-treat principles except that the missing outcome data are excluded; 3. the effect that corresponds to a full intention-to-treat analysis, where missing data have been imputed using methods that treat the imputed data as if they were observed (e.g. last observation carried forward, mean imputation, regression imputation, stochastic imputation); or 4. the effect that corresponds to an 'as-treated' or 'per-protocol' analysis, or an analysis from which eligible trial participants were excluded [4, 17]. The effect used in the assessment was recorded in the data extraction form.

#### B1.1.2 Assessment of risk of bias in NRSIs

We had planned to use ROBINS-I [18, 19] to assess risk of bias in NRSIs, however there were no NRSIs in the included studies.

### B1.2 Measures of treatment effect

We anticipated that many of the outcomes would be continuous (e.g. pain, anxiety), and that varying measurement instruments would be used to measure the same underlying construct across the studies. For this reason, we quantified the effects of Bowen therapy using the standardised mean difference (SMD) (implementing the Hedges’ adjusted *g* version). In trials where a continuous measure had been dichotomised (e.g. a continuous pain scale is dichotomised into improvement or no improvement) and analysed as binary outcomes, we re-expressed reported, or calculated, odds ratios as SMDs [20]. We did not report any of our meta-analysis results as dichotomous outcomes.

#### B1.2.1 Interpretation of treatment effects

Given the wide range of conditions, outcomes and measurement methods reported in the studies included in this review, it was not possible to specify thresholds for interpreting the size of the effect for each outcome measure. We planned to use Cohen’s guiding rules for interpreting SMDs where 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect [21]. In practice, our interpretation was based on whether there was an important effect or not [22, 23], with an SMD of 0.2 standard units set as the threshold for an important difference. If the SMD fell within the pre-specified range of -0.2 to 0.2 (i.e. within both thresholds), the effect of Bowen therapy was considered to be no different from control. An SMD above 0.2 or below -0.2 was interpreted as an important effect. We opted to use the most intuitive interpretation of effect estimates for each outcome, so positive values indicate benefit for some outcomes (an increase in health-related quality of life) and harm for other outcomes (an increase in pain). Because we were concerned that bias may be leading to exaggerated effect sizes, we chose not to describe the size of effect (i.e. we did not interpret effects as small, moderate or large).

### B1.3 Unit of analysis issues

There were no unit of analysis issues in studies included in this review (no studies with more than two eligible groups (arms) for a comparison, and no cluster or cross over trials).

### B1.4 Dealing with missing data

As planned in the protocol, we did not contact trial authors to obtain missing information (e.g. study characteristics, description of conduct of the trial) or aggregate level statistics (e.g. missing standard deviations). However, we attempted to calculate statistics necessary for meta-analysis using algebraic manipulation of reported statistics (e.g. computing the standard error for the treatment effect from a reported p-value). Studies for which we calculated or imputed statistics are annotated in forest plots. We planned to explore the impact of these decisions in sensitivity analyses but there were too few studies to do so. Studies for which we could not calculate or impute the statistics required for inclusion in the meta-analysis are listed in the forest plot and in Appendix E3 with reasons for why the results could not be included.

We planned to deal with missing outcome data within the primary trials through sensitivity analyses, where trials judged to be at a high risk of bias or some concerns would be excluded; however, this was not possible because there were too few trials included in the review [[1]](#footnote-2). Risk of bias ‘due to missing outcome data’ was considered within the overall bias judgement for each trial.

### B1.5 Assessment of heterogeneity

We assessed statistical heterogeneity of the intervention effects visually by inspecting the overlap of confidence intervals on the forest plots. While we report formal tests for heterogeneity using the χ 2 test (using a significance level of α=0.1), and quantified heterogeneity using the I2 statistic [25], these statistics are unlikely to be informative with so few studies. When there was evidence of heterogeneity, we judged its importance by considering where the point estimates for studies lay in relation to the threshold for an important difference (all on one side, indicating similar interpretations across the studies, or not).

### B1.6 Assessment of biases due to missing results

We used a framework for assessing risk of bias due to missing results in which an assessment is made for each meta-analysis regarding the risk and potential impact of missing results from studies in which we knew an outcome was measured but not reported (termed ‘known-unknowns’) and the risk of other missing studies or results (termed ‘unknown-unknowns’) [26]. The assessment of ‘known-unknowns’ involves assessment of whether trials meeting the inclusion criteria for a particular meta-analysis have missing results through examination of the publication’s methods section, trial registry entry (if available), and trial protocol (if available). We also examine the potential impact of studies for which data could not be included in the meta-analysis (see A1.1.1 Types of studies; A3.1 Selection of studies). We made an assessment as to whether the missing result was potentially due the result itself (e.g. ‘not statistically significant’), and whether inclusion of the result could lead to a notable change in the meta-analysis (e.g. if the missing result is from a large trial). These assessments are reported in the results section and considered in the GRADE assessment of publication bias.

We also planned to consider whether there was evidence of selective non-reporting of results from the assessment of ‘unknown unknowns’. In assessing ‘unknown-unknowns’, we planned to judge whether the trials not identified were likely to have results eligible for inclusion (i.e. for the outcome domain ‘pain’, is it likely that missing studies would have been eligible for inclusion in the overall analysis or for particular conditions). We were unable to use contour enhanced funnel plots to examine whether there was evidence of small study effects due to insufficient data [27]. We were also unable to undertake sensitivity analyses to compare the combined effect estimated from the random-effects model (primary analysis) with that estimated from a fixed (common) effect model due to insufficient data (together these analyses would inform a decision to downgrade for ‘suspected’ reporting (publication) bias). In the absence of these analyses, we considered whether there was concern about selective non-reporting arising from small study effects (multiple small studies reporting large effects) and evidence of selective non-reporting in the natural therapies literature more generally.

## B2 Data synthesis

### B2.1 Meta-analysis

Separate comparisons were set up for each population group and outcome domains agreed in the final framework (see Figure 3.5.1). Some comparisons were stratified by more specific conditions (with an overall estimate and estimate for each condition presented) (see Figure A6.1 Appendix A6). Subgroup analysis by population group was used to examine whether these population groups explained any observed statistical heterogeneity in the intervention effects (see Subgroup analysis).

We combined the effects using a random effects meta-analysis model, since we expected and found there to be clinical and methodological diversity across the trials that may contribute to statistical heterogeneity. These analyses used the restricted maximum likelihood estimator (REML) of between trial heterogeneity variance and the Hartung-Knapp-Sidik-Jonkman confidence interval method. Analyses were conducted in Stata Statistical Software [28].

Forest plots were used to visually depict the intervention effect estimates and their confidence intervals. Forest plots are stratified by condition and risk of bias (within population group). For completeness, results for all studies for which an effect estimate (SMD) could be calculated are presented on the forest plot, including where a single study contributed to the comparison. Studies that had missing or uninterpretable results, or for which an effect estimate (SMD) could not be calculated, are also depicted on the plot.

### B2.2 Summary and synthesis when meta-analysis is not possible

Studies that were eligible for the evidence synthesis but could not be included in meta-analyses, are included in the characteristics of included studies table (Appendix E1). These studies are counted as ‘missing results’ rather than included in a summary or other synthesis (i.e. the result was judged to be uninterpretable or there were major concerns about the integrity of the data). Details of the syntheses for which each of the studies was eligible are tabulated, together with the number of participants and the reason why data are missing (Appendix E3). We report available data from these analyses in forest plots and summary of findings tables, except where the authors report a result that is uninterpretable. We did not assess risk of bias because bias (under- or over-estimating the effect) is only relevant if results are included in a meta-analysis or reported. The reasons why these studies were not included in the analysis do not relate to bias (i.e. incomplete reporting of effects and their variances, errors in reporting or analysis of data, no information to interpret), so a risk of bias assessment would not characterise the problems with these studies.

### B2.3 Subgroup analysis and investigation of heterogeneity

For pain conditions, we undertook a subgroup analysis to examine whether population group explains any observed statistical heterogeneity in the intervention effects, using the pre-defined groups specified in the final framework (see Figure A6.1 for population groups in each meta-analysis). However, there are too few studies in this analysis to provide an interpretation of the results.

### B2.4 Sensitivity analyses

We planned to undertake and report sensitivity analyses examining if the meta-analysis estimates were robust to the meta-analysis mode, assumptions made to enable inclusion of results in the meta-analysis, and the impact of excluding studies at risk of bias. However, there were too few studies for these analyses.

### B2.5 Summary of findings tables and assessment of certainty of the body of evidence

We prepared GRADE summary of findings tables for each of the main comparisons, reporting results for critical and important outcome domains (up to seven). For each result, two authors (MM, SB) used the GRADE approach to assess our confidence in where the effect lies relative to our threshold for a small effect (the certainty of evidence) (see Measures of treatment effect). Disagreements were resolved through discussion. In accordance with detailed GRADE guidance [23, 29, 30], an overall GRADE of high, moderate, low or very low certainty is reported for each result based on whether there are serious, very serious or no concerns in relation to each of the following domains [22].

1. **Risk of bias**. We assessed the overall risk of bias across all studies contributing to each synthesised result. There were too few studies to perform sensitivity analyses to examine whether removing studies at high risk of bias or some concerns changed the direction or size of effect estimate importantly (a reduction in benefit or an increase in harm being most concerning) (see Sensitivity analyses) [[2]](#footnote-3). We therefore considered the weight that studies at risk of bias contributed to each result. Where the majority of studies were at high risk of bias, we rated down for very serious concerns.
2. **Imprecision**. We judged imprecision by examining where the 95% confidence interval for each pooled effect estimate lay in relation to our threshold for an important effect (an SMD of -0.2 or 0.2; see Measures of treatment effect). Where the confidence interval crossed a threshold leading to different interpretations (e.g. interpretation of the upper bound of the interval was ‘an important effect’ and the lower bound ‘little or no effect’), we considered rating down for imprecision. If the extent to which the confidence interval crossed the threshold was modest, and the interpretation was consistent with the point estimate, we did not rate down (e.g. if the upper bound of the confidence interval was an SMD of -0.15 and the point estimate -0.50). We rated down for serious imprecision if the confidence interval crossed one threshold (important benefit or important harm) and the interpretation of either the upper or lower bound of the interval was different from the point estimate (e.g. if the upper bound of the confidence interval was an SMD of 0.40 indicating an important increase in pain, and the point estimate was -0.15 indicating an unimportant reduction in pain). We rated down for very serious imprecision if the confidence interval crossed two thresholds (important benefit and important harm) and for extremely serious imprecision where the confidence interval was so wide that the result was considered uninterpretable. In line with GRADE guidance, we considered the likely impact of inconsistency when rating imprecision since inconsistency can contribute to imprecision [31, 32].
3. **Inconsistency**. We assessed whether there was important, unexplained inconsistency in results across studies considering the overlap of confidence intervals (non-overlap indicating potentially important differences in direction or size of effect). Where there was concerns about inconsistency based on non-overlapping confidence intervals, we considered where the point estimates lie in relation to the threshold for an important effect (if all to one side of a threshold, we were less concerned). While we calculated statistical measures to quantify and test for heterogeneity (I2 statistic, χ2 test), there were too few studies for these statistics to be informative. To enhance our interpretation of whether inconsistency is important, we planned to calculate and examine the prediction interval, considering whether it included values that lead to a different conclusion than an assessment based on the confidence interval [33]. However, this is only informative with more than 10 studies, so the method could not be used. Due to the small number of studies, we were unable to used results of subgroup analyses to explain the inconsistency (see Assessment of heterogeneity; specifically, the population subgroups). Where inconsistency was not explained, we rated down. Where a result was based on a single study, inconsistency was not rated [31].
4. **Indirectness.** We assessed whether there are important differences between the characteristics of studies included in each synthesis and the question we were seeking to address, such that the effects observed may not apply to our question (i.e. the applicability of the evidence). For example, differences between the interventions delivered and Bowen therapy practice in Australia that are likely to influence the size of effect. Where results came from a single small study, we were concerned that similar effects might not be observed in the population of interest more generally, and rated down for serious indirectness. Where the included studies addressed only part of the population of interest (e.g. the only form of acute pain was acute neck pain), we did not rate down for indirectness. Instead, we specified the population from which data came when interpreting results and indicated uncertainty for the population group more generally.
5. **Publication bias**. Our judgement of publication bias was based on assessment of bias due to missing results, primarily from interpretation of known unknowns as per Cochrane guidance for reviews with a small number of studies, where methods for investigating unknown unknowns are less useful (see Assessment of biases due to missing results). We planned to consider the potential impact of excluding studies in languages other than English, but did not identify any studies in languages other than English.
6. **Upgrading domains** (large effect size, dose response gradient, opposing plausible residual confounding). While, in principle, these domains apply to randomised trials, there is no precedent for rating up the evidence from randomised trials, and we did not have reason to apply them in this review.

Using GRADE decision rules, we derived an overall GRADE for the certainty of evidence for each result included in the summary of findings table [30]. A result from a body of evidence comprised of randomised trials begins as ‘high’ certainty evidence (score=4), and can be rated down (-1 or -2) for serious or very concerns on any GRADE domain that reduces confidence that Bowen therapy has an important effect (as determined by the pre-specified thresholds) [29, 30, 34]. As indicated above, we applied the most recent GRADE guidance which makes provision for rating down (-3) for extremely serious imprecision.

Summary of findings tables were prepared using the GRADEpro GDT software [23]. The tables include:

* estimates of the effects of Bowen therapy reported as standardised mean differences
* the overall GRADE (rating of certainty) and an explanation of the reason(s) for rating down (or borderline decisions) [35].
* the study design(s), number of studies and number of participants contributing data
* a plain language statement interpreting the evidence for each comparison and outcome, following GRADE guidance for writing informative statements (see B2.6 interpretation of findings) [36].

We present the certainty of evidence in summary of findings tables using one of four levels with the following symbols and interpretations.

|  |  |  |
| --- | --- | --- |
| **Certainty** | **GRADE interpretation** | **Implications** |
| High (⊕⊕⊕⊕) | we are very confident that the true effect lies close to that of the estimate of the effect | further research is very unlikely to change the confidence in the estimate of effect |
| Moderate (⊕⊕⊕⊝) | we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. | further research is likely to have an important impact in the confidence in the estimate of effect |
| Low (⊕⊕⊝⊝) | our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. | further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate |
| Very low (⊕⊝⊝⊝) | we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | any estimate of effect is very uncertain |

### B2.6 Interpretation of findings (evidence statements)

When interpreting results, we followed GRADE guidance for writing informative statements [36]. All interpretations are based on where the point estimate lies in relation to the pre-specified thresholds for an important effect (an important effect or not) and the direction of effect (beneficial or harmful). The certainty of evidence is communicated by qualifying the interpretation of effect (e.g. ‘probably’ improves for moderate certainty). For low certainty evidence the interpretation is qualified with the word ‘may’. For example, ‘Bowen therapy may improve pain’ indicates that the point estimate lies above the threshold for important benefit (an SMD >0.2) and that the evidence is of low certainty.

For very low certainty evidence, we do not provide an interpretation of the result except to state ‘The evidence is very uncertain about the effect of Bowen therapy on outcome’. This is one of two options that GRADE provides for interpreting findings based on very low certainty of evidence: “one option gives the direction of the effect, the other does not” [36]. The decision not to interpret very low certainty results was made independently by the NTWC to ensure a consistent and clear interpretation of findings across Natural Therapy Review reports (see Appendix G).

# References for Appendix A and B

1. National Health and Medical Research Council: Statement of requirement: Evidence evaluations for review of natural therapies (tranche two). 2020.

2. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. Journal of Clinical Epidemiology 2018;96:84-92.

3. World Health Organisation. International statistical classification of diseases and related health problems (11th ed.) Available from: <https://www.who.int/classifications/classification-of-diseases> Access date: 15 January 2021 2019

4. Higgins JPT, Savovic J, Page MJ, Sterne JAC. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). Available from <https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2>. Access date: 8 February 2021. 2019

5. Reeves BC, Deeks JJ, Higgins JPT, Shea B, Tugwell P, Wells G: **Chapter 24: Including non-randomized studies on intervention effects.** In *Cochrane Handbook for Systematic Reviews of Interventions version 63 (updated February 2022) Cochrane, 2022 Available from wwwtrainingcochraneorg/handbook.* Edited by Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, VA W

6. Reeves BC, Wells GA, Waddington H. Quasi-experimental study designs series-paper 5: a checklist for classifying studies evaluating the effects on health interventions-a taxonomy without labels. J Clin Epidemiol 2017;89:30-42.

7. Higgins JPT, Eldridge SM, Li T: Chapter 23: Including variants on randomized trials. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane. Available from [www.training.cochrane.org/handbook](file:///G%3A/My%20Drive/NHMRC%20natural%20therapies/other%20therapies/bowen/report/www.training.cochrane.org/handbook). (Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V eds.); 2020.

8. Steel A: PRACI Study: unpublished data. 2021.

9. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnson RV, Thomas J: **Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis.** In *Cochrane Handbook for Systematic Reviews of Interventions.* 2nd edition. Edited by Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Welch V. Chichester (UK): John Wiley & Sons; 2019

10. National Health and Medical Research Council: Bowen therapy description developed in conversation with the National Health and Medical Research Council’s Natural Therapies Working Committee Chair and the Department of Health’s Natural Therapies Review Expert Advisory Panel (February 2020). 2020.

11. National Health and Medical Research Council: Draft framework for protocols for systematic reviews of randomised controlled trials and non-randomised studies of interventions. 2020.

12. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.

13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381.

14. Hansen C, Taylor-Piliae RE. What is Bowenwork®? A systematic review. J Altern Complement Med 2011;17:1001-1006.

15. Steel A, Beacham B, Oyston E, Adams J. Characteristics of bowen therapy practitioners and practice in Australia: An exploratorysecondary analysis of the practitioner research and collaboration initiative (PRACI) practice-based research network. Journal of Bodywork and Movement Therapies 2024;38:459-463.

16. Hoffmann T, Glasziou P, Barbour V, Macdonald H. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;1687:1 - 13.

17. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.

18. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.

19. Sterne JAC, Higgins JPT, Elbers RG, Reeves BC, and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I): detailed guidance, updated 12 October 2016. Available from <http://www.riskofbias.info> [accessed 7 September 2022]. 2016

20. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000;19:3127-3131.

21. Schünemann HJ, Vist GE, Higgins J, Santesso N, Deeks JJ, Glasziou P, Akl EA, Guyatt GH, On behalf of the Cochrane GRADEing Methods Group: **Chapter 15: Interpreting results and drawing conclusions.** In *Cochrane Handbook for Systematic Reviews of Interventions.* 2nd edition. Edited by Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Welch V. Chichester (UK): John Wiley & Sons; 2019

22. Brennan SE, Johnston RV. Research Note: Interpreting findings of a systematic review using GRADE methods. Journal of Physiotherapy 2023

23. Zeng L, Brignardello-Petersen R, Hultcrantz M, Siemieniuk RAC, Santesso N, Traversy G, Izcovich A, Sadeghirad B, Alexander PE, Devji T, et al. GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 2021;137:163-175.

24. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.

25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.

26. Page MJ, Higgins JPT, Sterne JA: Chapter 13: Assessing risk of bias due to missing results in a synthesis. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane. Available from [www.training.cochrane.org/handbook](file:///G%3A/My%20Drive/NHMRC%20natural%20therapies/other%20therapies/bowen/report/www.training.cochrane.org/handbook). (Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V eds.); 2020.

27. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008;61:991-996.

28. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC. 2021

29. Schunemann HJ, Brozek J, Guyatt G, Oxman AD (Eds.): **Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach**. Hamilton, Canada: McMaster University; 2013.

30. Schünemann HJ, Higgins J, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH, On behalf of the Cochrane GRADEing Methods Group (formerly Applicability and Recommendations Methods Group) and the Cochrane Statistical Methods Group: **Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence.** In *Cochrane Handbook for Systematic Reviews of Interventions.* 2nd edition. Edited by Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Welch V. Chichester (UK): John Wiley & Sons; 2019

31. Guyatt G, Zhao Y, Mayer M, Briel M, Mustafa R, Izcovich A, Hultcrantz M, Iorio A, Alba AC, Foroutan F, et al. GRADE Guidance 36: Updates to GRADE's approach to addressing inconsistency. J Clin Epidemiol 2023

32. Zeng L, Brignardello-Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A, Traversy G, Akl EA, Mayer M, Schunemann HJ, Guyatt GH. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol 2022;150:216-224.

33. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med 2020;17:e1003082.

34. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, Alper BS, Meerpohl JJ, Murad MH, Ansari MT, et al. The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology 2017

35. Santesso N, Carrasco-Labra A, Langendam M, Brignardello-Petersen R, Mustafa RA, Heus P, Lasserson T, Opiyo N, Kunnamo I, Sinclair D, et al. Improving GRADE Evidence Tables part 3: Guidance for useful GRADE certainty in the evidence judgments through explanatory footnotes. J Clin Epidemiol 2016

36. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, Brignardello-Petersen R, Carrasco-Labra A, De Beer H, Hultcrantz M, et al. GRADE guidelines: 26. informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology 2019

# Appendix C. Lists of studies considered for review

## Overview of Appendix C – separate file

Appendix C is comprised of four parts (below).

These Appendices report the studies excluded at full text review with reason for exclusion, the public submissions and eligibility decision for each, the studies awaiting classification, and ongoing studies.

|  |
| --- |
| Appendix C1. Citation details of studies from search results excluded |
| Appendix C2. Citation details of studies from public submissions |
| Appendix C3. Citation details of studies awaiting classification |
| Appendix C4. Characteristics of ongoing studies |

# Appendix D. Citations for studies included in the evidence synthesis

|  |  |
| --- | --- |
| **Aslam 2023** | Aslam N, Kazmi Y, Maqbool A, Khalid MU, Hassan M, Mansha H. Effects of Bowen Technique in Postural Neck Pain among Dentists. Pakistan journal of medical and health sciences. 2023; 17(1) 14-16. doi: 10.53350/pjmhs202317114 |
| **Chee 2023** | Chee LA Yee, Tsz MA Lee, Pik Yu Chen, Samy W, Lap YF Au, Chi HD Siu. The Effect of ISBT-Bowen Therapy in the Treatment of Myofascial Neck Pain--a Randomized, Single-Blinded Clinical Trial. International journal of therapeutic massage & bodywork. 2023; 16(2) 29-38. doi: 10.3822/ijtmb.v16i2.801 |
| **Dalal 2020** | Dalal P, Kage V. Comparison of Ischaemic Compression, Myofascial Release and Bowens Technique In Non Specific Neck Pain-A Randomized Clinical Trial. Indian Journal of Applied Research. 2020; 10(1) |
| **Lee 2020** | Lee K, Lewis GN. Short term relief of multisite chronicpain with Bowen Therapy: A double-blind, randomized controlled trial. Journal of bodywork and movement therapies. 2020; 24(4) 271-279. doi: 10.1016/j.jbmt.2020.06.025 |
| **Seemal (Noor) 2022** | Seemal P, Noor R, Riaz S, Afzal H, Anwaar S, Niaz M. Effects of Muscle Energy Technique with and without Bowen Therapy in Text Neck Syndrome. Pakistan journal of medical and health sciences. 2022; 16(6) 164-166. doi: 10.53350/pjmhs22166164 |
| **Qamar 2023** | Qamar, Muhammad Mustafa; Basharat, Ayesha; Kiran, Qurba; Fatima, Ms. Effects of Bowen therapy in patients with tension-type headache: a randomized controlled trial. Pakistan Journal of Rehabilitation. 2023; 12(1) 27-33. doi: 10.36283/pjr.zu.12.1/005 |
|  |  |

# Appendix E. Characteristics of studies included in the review

## Overview of Appendix E – separate file

Appendix E is comprised of three parts, each in a separate file.

**Appendix E1** provides information about the characteristics of each of the studies eligible for the evidence synthesis.

* study ID, location, setting, and study design
* the population eligibility criteria, number of participants randomised, participant characteristics, and ICD codes
* the Bowen therapy treatment goal, and details about the Bowen therapy intervention(s) and comparator(s)
* a list of all reported outcome(s) categorised according to whether they were eligible or ineligible for the synthesis, the measurement method for each eligible outcome, the timing of outcome measurement, and the outcome(s) selected for inclusion in the synthesis for each outcome domain

**Appendix E2** provides information about funding, declaration of interest and ethics approval for each study.

**Appendix E3** provides a list of studies that were eligible for the evidence synthesis, but for which data could not be included in the meta-analysis. Details of the syntheses for which each of the studies was eligible are tabulated, together with the number of participants and reason why data are missing.

Studies were included in E1 and E2 irrespective of whether they provided data that could be included in the meta-analysis.

Appendices are as follows

|  |
| --- |
| E1. Characteristics of studies included in the evidence synthesis |
| E2. Funding sources, potential conflicts of interest and ethics approval for studies included in the evidence synthesis |
| E3. List of studies eligible for the evidence synthesis with data that could not be included for meta-analysis |

# Appendix F. Risk of bias assessments

All studies in this review were individually randomised, hence all assessments use the ROB 2 tools for trials with a parallel design. Assessments are presented in alphabetical order by study ID.

For each study, an assessment was done for each outcome and comparison contributing to the meta-analysis (MA; or where results could not be included in the MA but were tabulated).

For each study we report

* the comparison for the assessment,
* the outcome domain for the assessment,
* other outcomes included in MAs for the study (noting if the assessment was the same for these or other comparisons),
* the study design (parallel trial)

Where the RoB assessment was the same for all outcomes, comparisons or both, only one assessment is reported.

The assessment includes

* The overall risk of bias judgement
* The judgement for each domain, with an explanation provided for each signalling questions for which the response could lead to a judgement of high risk of bias or some concerns
* The response to each signalling question (numbers, the questions are reported in full below)

We did not assess studies that were counted as ‘missing results’ (i.e. those studies where the result was judged to be uninterpretable or where there were major concerns about the integrity of the data such that it would be misleading to report the results). In such cases, concerns about bias leading to an under- or over-estimate of effect are inconsequential compared to the impact of major errors in reported data or the interpretation of that data.

**Box F1**. Signalling questions from the revised Cochrane risk of bias (ROB 2) tool for randomised trials (parallel design)

| **Parallel (individually randomised)** |
| --- |
| **Domain 1.** Bias arising from the randomisation process |
| 1.1 Was the allocation sequence random? |
| 1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? |
| 1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? |
| **Domain 2.** Bias due to deviations from intended interventions |
| 2.1 Were participants aware of their assigned intervention during the trial? |
| 2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? |
| 2.3 If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the trial context? |
| 2.4 If Y/PY to 2.3 Were these deviations likely to have affected the outcome? |
| 2.5 If Y/PY to 2/4: Were these deviations from intended intervention balanced between groups? |
| 2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention? |
| 2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized? |
| **Domain 3**. Bias due to missing outcome data |
| 3.1 Were data for this outcome available for all, or nearly all, participants randomized? |
| 3.2 If N/PN/NI to 3.1a or 3.1b: Is there evidence that the result was not biased by missing data? |
| 3.3 If N/PN to 3.2 Could missingness in the outcome depend on its true value? |
| 3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? |
| **Domain 4**. Bias in the measurement of the outcome |
| 4.1 Was the method of measuring the outcome inappropriate? |
| 4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? |
| 4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study participants? |
| 4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? |
| 4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? |
| **Domain 5**. Bias from selection of the reported result |
| 5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis? |
| 5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? |
| 5.3 ... multiple eligible analyses of the data? |

| **Study ID. Chee 2023** | **Outcome domain.** pain | **Comparison.** Bowen v inactive |
| --- | --- | --- |
| **Assessments**. same RoB all outcomes: pain, EFMH, HRQOL, function | **Design.** parallel (individually randomised) |
| **Domain** | **Judgment** | **Explanation** (for concerns that lead to high or some concerns about RoB) | **Response to signalling questions** |
| SQ1 | SQ2 | SQ3 | SQ4 | SQ5 | SQ6 | SQ7 |
| 1. Bias arising from the randomisation process | Low |  | Y | PY | N |  |  |  |  |
| 2. Bias due to deviations from the intended intervention | Low | Intervention group received Bowen therapy and comparator ‘active’ standard care, so it is likely that participants were aware of their assigned intervention.The same people were involved in care for both arms and it is likely that they were aware of the participants’ assigned intervention.Modified intention-to-treat (mITT) analysis (excluding participants with missing outcome data) | Y | Y | PN | NA | NA | Y | NA |
| 3. Bias due missing outcome data | Low | I: 43/45 (4% missing), C: 41/45 (9% missing) | Y | NA | NA | NA |  |  |  |
| 4. Bias in the measurement of the outcome | Low | Participants (i.e. the outcome assessors) were aware that they had received either Bowen therapy or continued with their planned conventional treatment.However, Bowen therapy was compared to continuation of planned conventional treatment (e.g. physiotherapy, chiropractic therapy, acupuncture) and it is unlikely that participants would have prior beliefs about which intervention was more beneficial. | N | PN | Y | PN | NA |  |  |
| 5. Bias in the selection of the reported results | Low | No protocol or analysis plan, however the registry record shows pre-specified outcomes, measures and timepoints that are fully reported in the study report.Measures eligible for the meta-analysis appear fully reported in the paper, at multiple time points. It is unlikely that there were other results from which these measures were selectedResults are reported as summary statistics or with minimal analysis, and it is unlikely that these were selected from other analyses. | NI | PN | PN |  |  |  |  |
| **OVERALL risk of bias** | **Low** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

| **Study ID. Dalal 2020** | **Outcome domain.** pain | **Comparison.** Bowen v active (myofascial release) |
| --- | --- | --- |
| **Assessments**. pain | **Design.** parallel (individually randomised) |
| **Domain** | **Judgment** | **Explanation** (for concerns that lead to high or some concerns about RoB) | **Response to signalling questions** |
| SQ1 | SQ2 | SQ3 | SQ4 | SQ5 | SQ6 | SQ7 |
| 1. Bias arising from the randomisation process | Some concerns | "The subjects were then divided randomly into 3 groups". No further description of allocation sequence or concealment.Assessed on basis baseline outcome values. No baseline demographics reported. | PY | NI | PN |  |  |  |  |
| 2. Bias due to deviations from the intended intervention | High | Given similarities between interventions, it is unclear if participants were aware of their assigned intervention (not reported).Given the nature of the interventions, people delivering the interventions were aware of participant's assigned intervention. | NI | Y | PN | NA | NA | NI | NI |
| 3. Bias due missing outcome data | High |  | NI | N | NI | NI |  |  |  |
| 4. Bias in the measurement of the outcome | Low | Given the similarity of the interventions, it is unlikely that participants were aware of the intervention received (and if they were, it is unlikely there were prior beliefs about which intervention was more effective). | N | PN | PN | NA | NA |  |  |
| 5. Bias in the selection of the reported results | Some concerns | Results are reported as summary statistics or with minimal analysis, and it is unlikely that these were selected from other analyses. | NI | NI | PN |  |  |  |  |
| **OVERALL risk of bias** | **High** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

| **Study ID. Lee 2020** | **Outcome domain.** pain | **Comparison.** Bowen v inactive |
| --- | --- | --- |
| **Assessments**. pain, physical function | **Design.** parallel (individually randomised) |
| **Domain** | **Judgment** | **Explanation** (for concerns that lead to high or some concerns about RoB) | **Response to signalling questions** |
| SQ1 | SQ2 | SQ3 | SQ4 | SQ5 | SQ6 | SQ7 |
| 1. Bias arising from the randomisation process | Low |  | Y | Y | N |  |  |  |  |
| 2. Bias due to deviations from the intended intervention | Some concerns | In the Bowen group, 8/14 (57%) participants who completed the therapy believed they received a real treatment. In the sham therapy group, 7/15 (47%) participants who completed the therapy believed they received a real treatment. These values were not significantly different between two groups (P = 0.6). Given the nature of the interventions, people delivering the intervention were aware of the participants' assigned intervention.Naïve ‘per-protocol’ analysis (excluding trial participants who did not receive their assigned intervention)Low numbers in both groups. 2/16 (12.5%) of participants in intervention group did not received allocated intervention (withdrew during treatment; reasons unlikely associated with the outcome) | PN | Y | PN | NA | NA | N | PN |
| 3. Bias due missing outcome data | Low | I: 14/16 (12.5% missing), C: 15/15 (0% missing) | Y | NA | NA | NA |  |  |  |
| 4. Bias in the measurement of the outcome | Low | In the real therapy group, 8/14 (57%) participants who completed the therapy believed they received a real treatment. In the sham therapy group, 7/15 (47%) participants who completed the therapy believed they received a real treatment. These values were not significantly different between two groups (P = 0.6). | N | N | PN | NA | NA |  |  |
| 5. Bias in the selection of the reported results | Low | No protocol or analysis plan, however the registry record shows pre-specified outcomes, measures and timepoints that are fully reported in the study report.Measures eligible for the meta-analysis appear fully reported in the paper, at multiple time points. It is unlikely that there were other results from which these measures were selected.Results are reported for multiple ways of analysing/handling the NRS (summary statistics in figures and responder analysis), and it is unlikely that these were selected from other analyses. | NI | PN | PN |  |  |  |  |
| **OVERALL risk of bias** | **Some concerns** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

| **Study ID. Lee 2020** | **Outcome domain.** physical function | **Comparison.** Bowen v inactive |
| --- | --- | --- |
| **Assessments**. pain, physical function | **Design.** parallel (individually randomised) |
| **Domain** | **Judgment** | **Explanation** (for concerns that lead to high or some concerns about RoB) | **Response to signalling questions** |
| SQ1 | SQ2 | SQ3 | SQ4 | SQ5 | SQ6 | SQ7 |
| 1. Bias arising from the randomisation process | Low |  | Y | Y | N |  |  |  |  |
| 2. Bias due to deviations from the intended intervention | Some concerns | In the Bowen group, 8/14 (57%) participants who completed the therapy believed they received a real treatment. In the sham therapy group, 7/15 (47%) participants who completed the therapy believed they received a real treatment. These values were not significantly different between two groups (P = 0.6). Given the nature of the interventions, people delivering the intervention were aware of the participants' assigned intervention.Naïve ‘per-protocol’ analysis (excluding trial participants who did not receive their assigned intervention)Low numbers in both groups. 2/16 (12.5%) of participants in intervention group did not received allocated intervention (withdrew during treatment; reasons unlikely associated with the outcome) | PN | Y | PN | NA | NA | N | PN |
| 3. Bias due missing outcome data | Low | I: 14/16 (12.5% missing), C: 15/15 (0% missing) | Y | NA | NA | NA |  |  |  |
| 4. Bias in the measurement of the outcome | Low | In the real therapy group, 8/14 (57%) participants who completed the therapy believed they received a real treatment. In the sham therapy group, 7/15 (47%) participants who completed the therapy believed they received a real treatment. These values were not significantly different between two groups (P = 0.6). | N | N | PN | NA | NA |  |  |
| 5. Bias in the selection of the reported results | Low | No protocol or analysis plan, however the registry record shows pre-specified outcomes, measures and timepoints that are fully reported in the study report.Measures eligible for the meta-analysis appear fully reported in the paper, at multiple time points. It is unlikely that there were other results from which these measures were selected.Results are reported as summary statistics or with minimal analysis, and it is unlikely that these were selected from other analyses. | NI | PN | PN |  |  |  |  |
| **OVERALL risk of bias** | **Some concerns** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

| **Study ID. Seemal 2022** | **Outcome domain.** pain | **Comparison.** Bowen v inactive |
| --- | --- | --- |
| **Assessments**. same RoB for all outcomes: pain, function - disability | **Design.** parallel (individually randomised) |
| **Domain** | **Judgment** | **Explanation** (for concerns that lead to high or some concerns about RoB) | **Response to signalling questions** |
| SQ1 | SQ2 | SQ3 | SQ4 | SQ5 | SQ6 | SQ7 |
| 1. Bias arising from the randomisation process | High | "To conceal randomization sequentially numbered sealed opaque envelopes were prepared in advance and opened in sequence."It was likely that the person enrolling participants could predict the allocation sequence. | PY | PN | N |  |  |  |  |
| 2. Bias due to deviations from the intended intervention | High | Intervention group received Bowen therapy + muscle energy technique (MET) and comparator MET alone, so it is possible that participants were aware of their assigned intervention. | PY | NI | PN | NA | NA | NI | NI |
| 3. Bias due missing outcome data | High |  | NI | N | NI | NI |  |  |  |
| 4. Bias in the measurement of the outcome | Some concerns | Participants (i.e. the outcome assessors) were possibly aware that they had received Bowen + MET or MET alone.Participants’ knowledge of the intervention they received could have influenced their response. However, Bowen + MET was compared to MET alone, and it is unlikely that participants would have prior beliefs about which intervention was more beneficial. | N | N | PY | Y | PN |  |  |
| 5. Bias in the selection of the reported results | Low | No protocol or analysis plan, however the registry record shows pre-specified outcomes, measures and timepoints that are fully reported in the study report.Measures eligible for the meta-analysis appear fully reported in the paper, at multiple time points. It is unlikely that there were other results from which these measures were selected.Results are reported as summary statistics or with minimal analysis, and it is unlikely that these were selected from other analyses. | NI | PN | PN |  |  |  |  |
| **OVERALL risk of bias** | **High** |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |

# Appendix G. Differences between the protocol and the review

Changes from the protocol and methods not implemented

|  | **Section** | **Planned method** | **Change** | **Details (text, rationale or both)** |
| --- | --- | --- | --- | --- |
|  | A1. ObjectivesA1.1.3 | In our protocol, we planned an overall synthesis across any condition for each outcome domain. | Not done | The plan to synthesise across conditions was a contingency for reviews that included a large number of studies examining effects of diverse conditions. This was not the case for this review. As such, at the prioritisation step, the NHMRC endorsed a proposal to structure and report the summary and synthesis by population group, without reporting an overall analysis across conditions.  |
|  | A1. ObjectivesA1.1.3 | We planned to examine the effects of Bowen therapy compared to “evidence-based” treatments, in the exceptional circumstance that there were studies at low risk of bias that could be combined in a synthesis.  | All active comparators were included in synthesis | Due to the small number of eligible studies identified for the review, we reported on the effects of Bowen therapy compared to any active comparator (i.e. not limited to “evidence-based” treatments at low risk of bias that could be combined in a synthesis). |
|  | A1. ObjectivesA1.1.3 | We had planned to report the evidence examining the effects of Bowen therapy compared to other active comparators (i.e. not evidence-based' treatments) on an Evidence Inventory. | All active comparators were included in synthesis | Due to the small number of eligible studies identified for the review, we reported on the effects of Bowen therapy compared to any active comparator (i.e. not limited to “evidence-based” treatments). |
|  | A3.1 Selection of studies | We had planned to pilot title and abstract screening by three reviewers. | Change in process | We piloted title and abstract screening by two reviewers. |
|  | B1.2 Measure of treatment effects | We planned to use Cohen’s guiding rules for SMDs where 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. | We used a single threshold for an important effect (0.2) and did not interpret effect size.  | **Revised text (and rationale).** Because we were concerned that bias may be leading to exaggerated effect sizes, we chose not to describe the size of effect (i.e. we did not interpret effects as small, moderate or large) because this is likely to be misleading. **Implications.** This has no implications for the certainty of evidence because our a priori plan was to assess certainty in relation to whether there was an important effect or not (i.e. in relation to a threshold for an important difference of an SMD of 0.2), not our certainty in the magnitude of effect (trivial, small, moderate or large).  |
|  | B1.2 Measure of treatment effect | Where a valid and reliable minimal important difference (MID) is available for a familiar measure of relevance to the population groups in the meta-analysis, we will re-express the SMD in units of the measure and interpret the effect in relation to the MID if feasible to do so.  | We did not re-express SMDs in units of a familiar measure | **Rationale**. We followed GRADE and Cochrane guidance which recommends use of SMD for interpreting continuous outcomes in the absence of well-established MIDs. In addition using SMDs provided a consistent basis for interpretation across all results.  |
|  | B2.4 Sensitivity analysis | Analysis to examine if the meta-analysis estimates were robust to the meta-analysis mode, assumptions made to enable inclusion of results in the meta-analysis, and the impact of excluding studies at risk of bias.  | Could not be done | **Revised text.** There were too few studies to undertake these analyses. |
|  | B2.4 Sensitivity analysis | Our stated method was to undertake and report sensitivity analyses in which we excluded “trials judged to be at an overall high or unclear risk of bias.” | Terminology corrected (not a change to protocol) | **“**Unclear risk of bias” is the terminology used in the original ROB tool. Updated ROB2 terminology replaces this wording with “some concerns”.  |
|  | B2.5 Summary of findings tables and assessment of certainty of the body of evidence | We had planned for one author to assess the certainty of the body of evidence | Change in process | Two authors independently assessed the certainty of the body of evidence for each result, and any disagreements were resolved through discussion. |
|  | B2.5 GRADE assessments – risk of bias | As per B2.4 we did not use the term ‘some concerns’ when describing our approach to rating down for risk of bias | Terminology corrected (not a change to protocol) | The use of ‘some concerns’ is consistent with the ROB2 tool. Our approach to GRADE is consistent with that for sensitivity analyses where downgrades of -1 are considered where the majority of studies are rated as ‘some concerns’ or studies with the majority of weight in the analysis are rated as ‘high risk of bias’. Downgrades of -2 are made where most or all studies are at high risk of bias. Decisions not to rate down in these circumstances would be warranted if sensitivity analyses showed removal of studies at risk of bias did not materially alter the effect estimate.  |
|  | B2.6 Interpretation of findings | Our endorsed protocol stated that we would report “a plain language statement interpreting the evidence for each comparison and outcome, following GRADE guidance for writing informative statements”. We did not specify which option would be used for very low certainty evidence (i.e. give the direction of the effect, or limit to a statement that the ‘evidence is very uncertain’). | NTWC advised not to include direction of effect for very low certainty evidence.  | The decision not to interpret very low certainty results was made independently by the NTWC to ensure a consistent and clear interpretation of findings across Natural Therapy Review reports. This decision was made after endorsement of the protocol, and prior to preparation of the Bowen therapy review report. |
|  | B2.2Summary and synthesis when meta-analysis is not possible | For a particular comparison, if we are unable to analyse most of the effect estimates (due to incomplete reporting of effects and their variances, variability in the effect measures across the studies), we will consider alternative synthesis method. | Other synthesis methods not used. We report available data if interpretable. | **Rationale.** Where possible, we report available data and present the studies on the meta-analyses. We do not include these studies in another synthesis because the data are incompletely reported and any interpretation thereof would be inconsistent with that for other results.  |

# Appendix H. Response to comments from the Methodological review

Methodological review (or peer review) was conducted to appraise the methodological quality and assess the appropriateness of reporting for this systematic review (including appendices).

For reporting, the methodological review assessed the systematic review against the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Checklist (2020) and where applicable, the MECIR (Methodological Expectations of Cochrane Intervention Reviews) manual to ensure the systematic review was designed and conducted in accordance with:

* NHMRC’s Developing your Guideline module in NHMRC’s Guidelines for Guidelines Handbook
* Cochrane Handbook for Systematic Reviews of Interventions (updated 2022)
* GRADE guidance and GRADE working group criteria for determining whether the GRADE approach was used (GRADE handbook).

Assessment included the application of criteria for considering studies for the review and synthesis, search methods, data extraction and analysis, assessment of risk of bias of studies, assessment of the certainty of evidence using GRADE, and the interpretation and summary of findings.

The systematic review (including appendices) has been updated to reflect the amendments suggested by methodological review and NHMRC’s Natural Therapies Working Committee, where appropriate. In summary, updates included additional information and/ or clarification of the Plain Language Summary, Executive Summary, Results sections and Appendices, including:

* GRADE judgements clarified and confirmed where appropriate.
* Clarifications to the PRISMA diagram.
* Rewording and additional explanatory text in various parts of the report to improve clarity.

A detailed record of responses to all comments indicating changes that were made was provided to NHMRC together with the amended Report and Appendices documents.

# Appendix I. Abbreviations

Below is a list of abbreviations used in the report. Abbreviations for outcome measures are in a table following the list.

**AMED:** Allied and Complementary Medicine Database

**CAM:** complementary and alternative medicine

**CENTRAL:** Cochrane Central Register of Controlled Trials

**CINAHL:** Cumulative Index of Nursing and Allied Health Literature

**CI:** confidence interval

**CM:** Complementary Medicine

**COMET:** Core Outcome Measures in Effectiveness Trials

**CTM:** connective tissue massage

**DEFF:** design effect

**EUROPE PMC:** Europe PubMed Central

**GRADE:** Grading of Recommendations, Assessment, Development and Evaluation

**HR-QoL:** health-related quality of life

**ICC:** intra-cluster correlation

**ICD-11:** International Classification of Diseases 11th Revision

**ICTRP:** International Clinical Trials Registry Platform

**MA: Meta-analysis**

**MeSH:** Medical Subject Headings

**MID:** minimal important difference

**NHMRC:** National Health and Medical Research Council

**NRSI:** non-randomised study of interventions

**NTREAP:** Natural Therapies Review Expert Advisory Panel

**NTWC:** Natural Therapies Working Committee

**PICO:** population, intervention, comparator, outcome

**PRACI:** Practitioner Research and Collaboration Initiative

**PRISMA:** Preferred Reporting Items for Systematic review and Meta-Analyses

**PRISMA-P:** Preferred Reporting Items for Systematic review and Meta-Analyses Protocols

**PROSPERO:** International prospective register of systematic reviews

**RCT:** randomised controlled trial

**REML:** restricted maximum likelihood estimator

**ROB:** risk of bias

**RR:** risk ratios

**SMD:** standardised mean difference

**TIDieR:** Template for Intervention Description and Replication

**TGA:** Therapeutic Goods Administration

**Abbreviations for measures reported in this review**

| **Abbreviation** | **Measure** |
| --- | --- |
| BPI | Brief Pain Inventory |
| CUDOS | Clinically Useful Depression Outcome Scale |
| DASH | Disabilities of the Arm, Shoulder and Hand |
| DASS | Depression, Anxiety and Stress Scale |
| GAD-7 | General Anxiety Disorder-7 |
| HADS | Hospital Anxiety and Depression Scale |
| JSEQ | Jenkins Sleep Evaluation Questionnaire |
| LLTQ | Lower Limb Tasks Questionnaire |
| MAF | Multidimensional Assessment of Fatigue |
| NDI | Neck Disability Index  |
| NPRS | Numeric Pain Rating Scale  |
| NRS | Numerical Rating Scale  |
| ODI | Oswestri Low Back Disability Index |
| PHQ-9 | Patient Health Questionnaire-9 |
| PROMIS | Patient-Reported Outcomes Measurement Information System |
| PSQI | Pittsburgh Sleep Quality Index |
| SF-12 | 12-item Short Form Health Survey |
| SF-36 | 36-item Short Form Health Survey |
| SFMPQ-II | Short-Form McGill Pain Questionnaire-9  |
| SPADI | Shoulder Pain and Disability Index |
| VAS | Visual Analogue Scale  |

1. In the protocol we reported that we would conduct sensitivity analyses excluding trials judged at high or unclear risk of bias. The terminology “Unclear risk of bias” has been replaced in ROB2 with “some concerns”. The approach described here is consistent with the protocol in that the sensitivity analyses were to be restricted to studies at low risk of bias. [↑](#footnote-ref-2)
2. In the protocol we reported that we would conduct sensitivity analyses excluding trials judged at high or unclear risk of bias. to “Unclear risk of bias” has been replaced in ROB2 with “some concerns”, which is the term we should have used. However, the approach described here is consistent with the protocol in that the sensitivity analyses were to be restricted to studies at low risk of bias. [↑](#footnote-ref-3)